PUBLISHER: The Business Research Company | PRODUCT CODE: 1720725
PUBLISHER: The Business Research Company | PRODUCT CODE: 1720725
Biliary tract cancer (BTC), also known as cholangiocarcinoma, is a rare malignancy that develops in the bile ducts, gallbladder, or ampulla of Vater. This cancer disrupts bile flow, which is essential for digestion and waste elimination. Research and treatment efforts focus on early detection, advancing therapeutic options, and improving survival rates for affected patients.
The primary types of biliary tract cancer include intrahepatic bile duct cancer, extrahepatic bile duct cancer, and gallbladder cancer. Intrahepatic cholangiocarcinoma is a rare liver cancer affecting the bile ducts, potentially leading to bile flow obstruction. Treatment options include chemotherapy, targeted therapy, and immunotherapy, catering to various end users such as hospitals, specialty cancer centers, ambulatory surgical centers, and others.
The biliary tract cancer market research report is one of a series of new reports from The Business Research Company that provides biliary tract cancer market statistics, including the biliary tract cancer industry global market size, regional shares, competitors with the biliary tract cancer market share, detailed biliary tract cancer market segments, market trends, and opportunities, and any further data you may need to thrive in the biliary tract cancer industry. This biliary tract cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The biliary tract cancer market size has grown strongly in recent years. It will grow from $0.67 billion in 2024 to $0.72 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth during the historic period can be attributed to the rising incidence of biliary tract cancer, increasing demand for effective therapies, a surge in risk factors such as obesity, an aging population, and greater investment in research and development.
The biliary tract cancer market size is expected to see strong growth in the next few years. It will grow to $0.95 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to lifestyle changes, increasing awareness, early detection initiatives, favorable reimbursement policies, and supportive government policies. Key trends expected during this period include technological advancements in diagnosis and treatment, the adoption of immunotherapy, rising demand for precision medicine, evolving treatment approaches, and advancements in biomarker-based therapies.
The rising prevalence of obesity is expected to drive the growth of the biliary tract cancer market. Obesity is a chronic medical condition characterized by excessive fat accumulation that negatively impacts health. Several factors contribute to the increasing obesity rates, including physical inactivity, psychological influences, aging, and genetic or biological factors. Obesity promotes chronic inflammation, insulin resistance, and excessive bile acid secretion, leading to DNA damage and tumor formation. It also disrupts hormonal balance and metabolism, creating a cancer-prone environment in the biliary tract. For example, in September 2023, the Centers for Disease Control and Prevention (CDC), a US-based government agency, reported that in 2022, the number of states with an adult obesity rate of 35% or higher increased to 22, up from 19 in 2021. As a result, the growing prevalence of obesity is fueling the expansion of the biliary tract cancer market.
Leading companies in the biliary tract cancer market are developing advanced combination therapies to improve treatment efficacy and patient outcomes. Combination therapy involves using two or more medications or treatment approaches simultaneously to enhance effectiveness. For instance, in November 2023, Merck & Co. Inc., a US-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for KEYTRUDA (pembrolizumab) in combination with gemcitabine and cisplatin for treating patients with locally advanced unresectable or metastatic biliary tract cancer (BTC). This approval was based on results from the Phase 3 KEYNOTE-966 trial, which demonstrated a statistically significant improvement in overall survival, reducing the risk of death by 17% compared to chemotherapy alone. Patients receiving the combination therapy had a median overall survival of 12.7 months, compared to 10.9 months for those on chemotherapy alone, marking a major advancement in treatment options for this challenging cancer.
In December 2022, Jazz Pharmaceuticals plc, an Ireland-based pharmaceutical company, partnered with Zymeworks Inc. to develop and commercialize zanidatamab, a HER2-targeted bispecific antibody. This collaboration was driven by promising results from the HERIZON-BTC-01 pivotal trial for biliary tract cancers. Zymeworks Inc. is a Canada-based biotechnology company specializing in the development of biliary tract cancer drugs.
Major players in the biliary tract cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc, Eli Lily and Company, Boehringer Ingelheim International GmbH, Eisai Co. Ltd., Servier Pharmaceuticals, Jazz Pharmaceuticals plc, Incyte Corporation, BeiGene LTD., Zymeworks, Basilea Pharmaceutica Ltd., Taiho Oncology Inc., RenovoRx Inc., TransThera Sciences Inc., QED Therapeutics Inc., and Helsinn Group.
North America was the largest region in the biliary tract cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in biliary tract cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the biliary tract cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The biliary tract cancer market consists of revenues earned by entities by providing services such as diagnosis and screening services, supportive care, clinical trials, and research. The market value includes the value of related goods sold by the service provider or included within the service offering. The biliary tract cancer market also includes sales of surgical instruments, pain management medications, and diagnostic tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Biliary Tract Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on biliary tract cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for biliary tract cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biliary tract cancer market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.